Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2021 | Trial design for myeloma patients based on aging rather than age

Gordon Cook • 2 Mar 2021
EMN 2021
Multiple Myeloma Dexamethasone Ixazomib Lenalidomide
Myeloma XIV

Gordon Cook, MB ChB, PhD, FRCP(Glas), FRCPath, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares an overview of his talk at EMN 2021 on novel trial designs based on aging rather than age for myeloma patients. Prof. Cook discusses the impact of accelerated aging on the ability to tolerate anti-cancer therapy. The IMWG frailty score is used to prognosticate patients, however, this scale has never been tested as a predictive biomarker. The Phase III Myeloma XIV trial (NCT03720041) will investigate whether the IMWG frailty score can be used as a predictive biomarker. This interview took place during the 2021 European Myeloma Network (EMN) congress.

More from Gordon Cook

2:13
How immunotherapies are changing the myeloma treatment landscape & future outlooks
Gordon Cook • 28 Sep 2023
4:03
Developments in assessing frailty in patients with multiple myeloma
Gordon Cook • 28 Sep 2023
1:05
Considerations for frailty adapted treatment approaches in multiple myeloma
Gordon Cook • 28 Sep 2023
3:23
MRD-directed trials & achieving MRD negativity in patients with high-risk multiple myeloma
Gordon Cook • 26 Aug 2022

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals